Precision BioSciences Stock Forecast, Price & News

+0.14 (+1.63 %)
(As of 04/14/2021 12:00 AM ET)
Today's Range
Now: $8.71
50-Day Range
MA: $10.63
52-Week Range
Now: $8.71
Volume902,805 shs
Average Volume1.02 million shs
Market Capitalization$496.35 million
P/E RatioN/A
Dividend YieldN/A
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:DTIL
Year FoundedN/A



Sales & Book Value

Annual Sales$22.24 million
Book Value$2.72 per share


Net Income$-92,880,000.00
Net Margins-484.81%


Market Cap$496.35 million
Next Earnings Date5/21/2021 (Estimated)
OptionableNot Optionable


Precision BioSciences (NASDAQ:DTIL) Trading Down 5.5%
April 6, 2021 |
Precision BioSciences Announces CEO Transition Plan
April 6, 2021 |
Precision BioSciences (NASDAQ:DTIL) Stock Price Up 5.6%
March 25, 2021 |
ROCE Insights For Precision BioSciences
March 18, 2021 |
See More Headlines


Overall MarketRank

1.53 out of 5 stars

Medical Sector

470th out of 2,019 stocks

Biological Products, Except Diagnostic Industry

69th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
+0.14 (+1.63 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

Is Precision BioSciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Precision BioSciences stock.
View analyst ratings for Precision BioSciences
or view top-rated stocks.

What stocks does MarketBeat like better than Precision BioSciences?

Wall Street analysts have given Precision BioSciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Precision BioSciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 6,010,000 shares, an increase of 73.2% from the March 15th total of 3,470,000 shares. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is presently 5.7 days. Currently, 13.5% of the company's stock are sold short.
View Precision BioSciences' Short Interest

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Precision BioSciences

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) released its quarterly earnings data on Wednesday, March, 17th. The company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.50) by $0.06. Precision BioSciences had a negative trailing twelve-month return on equity of 105.74% and a negative net margin of 484.81%.
View Precision BioSciences' earnings history

How has Precision BioSciences' stock price been impacted by Coronavirus (COVID-19)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DTIL stock has increased by 34.2% and is now trading at $8.71.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DTIL?

5 brokers have issued 12-month target prices for Precision BioSciences' shares. Their forecasts range from $14.00 to $27.00. On average, they expect Precision BioSciences' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 129.6% from the stock's current price.
View analysts' price targets for Precision BioSciences
or view top-rated stocks among Wall Street analysts.

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 44, Pay $562.1k)
  • Mr. Dario Scimeca, Gen. Counsel & Sec. (Age 46, Pay $319.96k)
  • Dr. Christopher R. Heery, Chief Medical Officer (Age 41, Pay $444.03k)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. John Alexander Kelly, Chief Corp. Affairs Officer & Interim CFO (Age 54)
  • Dr. David S. Thomson Ph.D., Chief Operating Officer (Age 60)
  • Mr. Shane Barton, VP, Corp. Controller & Interim Principal Accounting Officer (Age 51)
  • Dr. Derek Jantz Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 45)
  • Mr. Bruce Stevens, VP of Quality & Compliance
  • Ms. Heather King, Director of Marketing Communications & PR

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences CEO Matt Kane on Matt Kane has an approval rating of 100% among Precision BioSciences' employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an IPO on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include Thomasville National Bank (0.10%) and Pacer Advisors Inc. (0.01%). Company insiders that own Precision BioSciences stock include Christopher Heery, David S Thomson, Derek Jantz and Matthew R Kane.
View institutional ownership trends for Precision BioSciences

Which major investors are selling Precision BioSciences stock?

DTIL stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank. Company insiders that have sold Precision BioSciences company stock in the last year include David S Thomson, Derek Jantz, and Matthew R Kane.
View insider buying and selling activity for Precision BioSciences
or view top insider-selling stocks.

Which major investors are buying Precision BioSciences stock?

DTIL stock was bought by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Precision BioSciences
or or view top insider-buying stocks.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $8.71.

How much money does Precision BioSciences make?

Precision BioSciences has a market capitalization of $496.35 million and generates $22.24 million in revenue each year. The company earns $-92,880,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

How many employees does Precision BioSciences have?

Precision BioSciences employs 231 workers across the globe.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is

Where are Precision BioSciences' headquarters?

Precision BioSciences is headquartered at 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]

This page was last updated on 4/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.